1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 32, 10, 1, 16, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Osteoarthritis Pain - Overview
- Osteoarthritis Pain - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Osteoarthritis Pain - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteoarthritis Pain - Companies Involved in Therapeutics Development
- Osteoarthritis Pain - Drug Profiles
- Osteoarthritis Pain - Dormant Projects
- Osteoarthritis Pain - Discontinued Products
- Osteoarthritis Pain - Product Development Milestones
- Featured News & Press Releases
- Jul 18, 2022: OliPass moves forward to second stage of phase 2a trial for pain killer OLP-1002
- Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
- Jun 27, 2022: Virpax will pursue direct to OTC Pathway for Epoladerm for pain associated with osteoarthritis
- Jun 01, 2022: AlzeCure's abstract on pain Project TrkA-NAM accepted for presentation at IASP 2022
- May 02, 2022: Gordon Robert Alton, PhD joins BriOri BioTech as COO to develop patented topical formulation of Vioxx providing those suffering with osteoarthritis a long lasting non-opioid option for pain relief
- Apr 20, 2022: Ampio provides regulatory update
- Mar 22, 2022: Virpax completes all FDA-required pre-clinical studies for Epoladerm
- Mar 09, 2022: BriOri BioTech granted patent for topical formulation of Vioxx
- Mar 02, 2022: Xalud Therapeutics doses first patient in phase 2a trial of XT-150 for the treatment of facet joint osteoarthritis pain
- Feb 15, 2022: BriOri BioTech granted patent for topical formulation of Rofecoxib
- Dec 17, 2021: Xalud Therapeutics receives FDA Fast Track Designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee
- Dec 07, 2021: Sorrento begins enrollment in phase 2 trial of resiniferatoxin (RTX) for the treatment of pain due to knee osteoarthritis (OA)
- Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.
- Oct 26, 2021: Paradigm: Phase 2 synovial fluid biomarker study update
- Oct 14, 2021: Antibe Therapeutics provides update on Otenaproxesul and expanded drug pipeline
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Osteoarthritis Pain, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Osteoarthritis Pain - Pipeline by Acadia Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Achelios Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Adolore Biotherapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by AlzeCure Pharma AB, 2022
- Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Andros Pharmaceuticals Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by AntalGenics SL, 2022
- Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Apimeds Inc, 2022
- Osteoarthritis Pain - Pipeline by APT Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Aquilus Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by AstraZeneca Plc, 2022
- Osteoarthritis Pain - Pipeline by Avecho Biotechnology Ltd, 2022
- Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by BioTissue Inc, 2022
- Osteoarthritis Pain - Pipeline by BriOri BioTech Inc, 2022
- Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, 2022
- Osteoarthritis Pain - Pipeline by Chromocell Corp, 2022
- Osteoarthritis Pain - Pipeline by Concentric Analgesics Inc, 2022
- Osteoarthritis Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Eccogene (Shanghai) Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Eli Lilly and Co, 2022
- Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Ensign Pharmaceutical Inc, 2022
- Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by EyePoint Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Futura Medical Plc, 2022
- Osteoarthritis Pain - Pipeline by Grunenthal GmbH, 2022
- Osteoarthritis Pain - Pipeline by GSK plc, 2022
- Osteoarthritis Pain - Pipeline by Levicept Ltd, 2022
- Osteoarthritis Pain - Pipeline by Neumentum Inc, 2022
- Osteoarthritis Pain - Pipeline by Novartis AG, 2022
- Osteoarthritis Pain - Pipeline by Olatec Therapeutics LLC, 2022
- Osteoarthritis Pain - Pipeline by OliPass Corporation, 2022
- Osteoarthritis Pain - Pipeline by Overseas Pharmaceuticals Ltd, 2022
- Osteoarthritis Pain - Pipeline by Pacira BioSciences Inc, 2022
- Osteoarthritis Pain - Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
- Osteoarthritis Pain - Pipeline by Peptide Logic LLC, 2022
- Osteoarthritis Pain - Pipeline by Pfizer Inc, 2022
- Osteoarthritis Pain - Pipeline by Pharmnovo AB, 2022
- Osteoarthritis Pain - Pipeline by Pike Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Propella Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by ProteoThera Inc, 2022
- Osteoarthritis Pain - Pipeline by Pure Green Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Q-State Biosciences Inc, 2022
- Osteoarthritis Pain - Pipeline by RaQualia Pharma Inc, 2022
- Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by RHNanopharmacuticals LLC, 2022
- Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, 2022
- Osteoarthritis Pain - Pipeline by Sansho Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Saol Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Shanghai Leado Pharmaceutical Technology Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Shulov Innovative Science Ltd, 2022
- Osteoarthritis Pain - Pipeline by Sorrento Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Symic Bio Inc, 2022
- Osteoarthritis Pain - Pipeline by Techfields Pharma Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Tris Pharma Inc, 2022
- Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Virpax Pharmaceuticals Inc, 2022
- Osteoarthritis Pain - Pipeline by Xalud Therapeutics Inc, 2022
- Osteoarthritis Pain - Pipeline by Xgene Pharmaceutical Inc, 2022
- Osteoarthritis Pain - Pipeline by Xintela AB, 2022
- Osteoarthritis Pain - Pipeline by Yooyoung Pharm Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
- Osteoarthritis Pain - Pipeline by ZYUS Life Sciences Inc, 2022
- Osteoarthritis Pain - Dormant Projects, 2022
- Osteoarthritis Pain - Discontinued Products, 2022
- Osteoarthritis Pain - Discontinued Products, 2022 (Contd..1)
List of Figures
- Number of Products under Development for Osteoarthritis Pain, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acadia Pharmaceuticals Inc
- Achelios Therapeutics Inc
- Adolore Biotherapeutics Inc
- AlzeCure Pharma AB
- Ampio Pharmaceuticals Inc
- Andros Pharmaceuticals Co Ltd
- AntalGenics SL
- Antibe Therapeutics Inc
- Apimeds Inc
- APT Therapeutics Inc
- Aquilus Pharmaceuticals Inc
- AstraZeneca Plc
- Avecho Biotechnology Ltd
- Axsome Therapeutics Inc
- Beijing Tide Pharmaceutical Co Ltd
- BioTissue Inc
- BriOri BioTech Inc
- Centrexion Therapeutics Corp
- Chromocell Corp
- Concentric Analgesics Inc
- Daewoong Pharmaceutical Co Ltd
- Eccogene (Shanghai) Co Ltd
- Eli Lilly and Co
- Elite Pharmaceuticals Inc
- Ensign Pharmaceutical Inc
- Eupraxia Pharmaceuticals Inc
- EyePoint Pharmaceuticals Inc
- Futura Medical Plc
- Grunenthal GmbH
- GSK plc
- Levicept Ltd
- Neumentum Inc
- Novartis AG
- Olatec Therapeutics LLC
- OliPass Corporation
- Overseas Pharmaceuticals Ltd
- Pacira BioSciences Inc
- Paradigm Biopharmaceuticals Ltd
- Peptide Logic LLC
- Pfizer Inc
- Pharmnovo AB
- Pike Therapeutics Inc
- Propella Therapeutics Inc
- ProteoThera Inc
- Pure Green Pharmaceuticals Inc
- Q-State Biosciences Inc
- RaQualia Pharma Inc
- Regeneron Pharmaceuticals Inc
- RHNanopharmacuticals LLC
- Rottapharm Biotech Srl
- Sansho Co Ltd
- Saol Therapeutics Inc
- Shanghai Leado Pharmaceutical Technology Co Ltd
- Shionogi & Co Ltd
- Shulov Innovative Science Ltd
- Sorrento Therapeutics Inc
- Symic Bio Inc
- Techfields Pharma Co Ltd
- Tris Pharma Inc
- Vertex Pharmaceuticals Inc
- Virpax Pharmaceuticals Inc
- Xalud Therapeutics Inc
- Xgene Pharmaceutical Inc
- Xintela AB
- Yooyoung Pharm Co Ltd
- Zhejiang Yatai Pharmaceutical Co Ltd
- ZYUS Life Sciences Inc
